Actively Recruiting
Interrupting Sedentary Time to Improve Cardiometabolic Health and Toxicity in Patients With Lymphoma Receiving Chemotherapy: The iSTAND Trial
Led by Dana-Farber Cancer Institute · Updated on 2026-04-13
24
Participants Needed
1
Research Sites
82 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This study aims to see if a 12-week exercise program designed to reduce long periods of inactivity is feasible in newly diagnosed lymphoma participants receiving R-CHOP or POLA-R-CHP chemotherapy treatments, and whether it can improve heart health and reduce chemotherapy drug side effects.
CONDITIONS
Official Title
Interrupting Sedentary Time to Improve Cardiometabolic Health and Toxicity in Patients With Lymphoma Receiving Chemotherapy: The iSTAND Trial
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Ability to understand and willing to sign informed consent before study procedures
- Diagnosed with lymphoma
- Will receive first line R-CHOP or POLA-R-CHP chemotherapy, no specific timing from diagnosis required
- Aged 18 years or older
- Engaging in 60 minutes or less of structured moderate or vigorous exercise
- Have physician clearance to participate in exercise
- Speak English
- Willing to travel to Dana-Farber Cancer Institute for data collection and exercise sessions
- Have access to a phone that can receive text messages
You will not qualify if you...
- Unstable medical conditions preventing participation in moderate-to-vigorous exercise
- Participated in more than 60 minutes of structured moderate-to-vigorous exercise per week in the last month
- Receiving treatment for other active cancers except basal cell carcinoma
- Currently taking weight loss medications
- Unable to comply with study safety monitoring requirements
- Unable to travel to Dana-Farber Cancer Institute for data collection and chemotherapy infusions
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Dana Farber Cancer Institute
Boston, Massachusetts, United States, 02215
Actively Recruiting
Research Team
C
Christina Dieli-Conwright, MD, PhD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
SUPPORTIVE_CARE
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here